394 results about "Acetylcholine breakdown" patented technology

The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an A.beta..sub.42 lowering agent to a mammal under conditions in which levels of A.beta..sub.42 are selectively reduced, levels of A.beta..sub.38 are increased, and levels of A.beta..sub.40 are unchanged. The invention provides methods and materials for developing and identifying A.beta..sub.42 lowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease. The invention also provides compositions of A.beta..sub.42 lowering agents and antioxidants, A.beta..sub.42 lowering agents and non-selective secretase inhibitors, as well as A.beta..sub.42 lowering agents and acetylcholinesterase inhibitors. The invention also provides kits containing A.beta..sub.42 lowering agents, antioxidants, non-selective secretase inhibitors, and/or acetylcholinesterase inhibitors as well as instructions related to dose regimens for A.beta..sub.42 lowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors.

RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na⁺/K⁺-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.

Methods and compositions of the invention employ acetylcholinesterase (ACE) inhibitors to prevent and treat diseases and other disorders of the central nervous system (CNS), including Alzheimer's disease. ACE inhibitors are administered for targeted delivery to the CNS, for example by intranasal delivery. The methods and compositions of the present invention yield therapeutic concentrations of ACE inhibitors in a CNS tissue or compartment without the attendant disadvantages, risks and side effects of oral or injection delivery. Exemplary ACE inhibitors for use within the invention include galantamine and various salts and derivatives of galantamine. Carboxylate salts of galantamine (e.g., galantamine gluconate, galantamine lactate, galantamine citrate and galantamine glucarate) described herein exhibit a significant increase in solubility compared to other forms of galantamine, such as galantamine hydrobromide.

The present invention provides a novel compound having an excellent acetylcholinesterase inhibitory effect. That is, it provides a 4-substituted piperidine compound fluoride represented by the following formula, a pharmaceutically acceptable salt thereof or hydrates thereof (provided that 1-benzyl-4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine, a pharmaceutically acceptable salt thereof and hydrates thereof are excluded).wherein R<1 >and R<2 >represent substituents.

Agents for improving potentcy of the urinary bladder which comprises an amine compound of non-carbamate-type having an acetylcholinesterase-inhibiting action. Particularly, crystals of a tricyclic, condensed, heterocyclic derivative are provided, which possess an excellent action to inhibit acetylcholine esterase and an action to improve the excretory potency of urinary bladder. As an example, crystals of of 8-[3-[1-[(3-fluorophenyl)-methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one or a salt thereof and pharmaceutical compositions containing them are disclosed.

The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an Aβ₄₂ lowering agent to a mammal under conditions in which levels of Aβ₄₂ are selectively reduced, levels of Aβ₃₈ are increased, and levels of Aβ₄₀ are unchanged. The invention provides methods and materials for developing and identifying Aβ₄₂ lowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease. The invention also provides compositions of Aβ₄₂ lowering agents and antioxidants, Aβ₄₂ lowering agents and non-selective secretase inhibitors, as well as Aβ₄₂ lowering agents and acetylcholinesterase inhibitors. The invention also provides kits containing Aβ₄₂ lowering agents, antioxidants, non-selective secretase inhibitors, and/or acetylcholinesterase inhibitors as well as instructions related to dose regimens for Aβ₄₂ lowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors.

The invention relates to a novel scutellarin aglycon 4 (1)-position carbamate derivant (1), a preparation method and the application thereof. A pharmacological experiment proves that the compounds have obvious inhibitory activity of acetylcholinesterase and have protective effect with different degrees on PC12 cell trauma induced by H2O2, so the compounds can be used for preparing the drugs for treating neurodegenerative diseases such as vascular dementia, AD (presenile dementia), etc.

A composition and a method for using the composition to delay the onset of the symptoms of Alzheimer's disease in humans, comprising curcumin, piperine, oleic acid, oleanolic acid, ursolic acid, galantamine, and huperzine A, among other compounds. Curcumin is an antioxidant, while galantamine and huperzine A inhibit the activity of acetylcholinesterase in the brain. Piperine and oleic acid increase the bioavailability and gastrointestinal absorption of curcumin, galantamine, huperzine A, and other nutrients.

The invention provides construction of a surface plasma resonance sensor based on the amplification effect of a magnetic molecularly imprinted polymer and the application of the surface plasma resonance sensor in pesticide detection, and belongs to the technical field of surface plasma resonance sensing. Chlorpyrifos is regarded as a template molecule firstly; the magnetic molecularly imprinted polymer which has recognition action on the chlorpyrifos is compounded by adopting the self-polymerization performance of dopamine; after elution is performed on the chlorpyrifos, the magnetic molecularly imprinted polymer containing imprinted cavities has good superparamagnetism and high selectivity; the specific interaction between acetylcholinesterase fixed on the surface of a gold sheet and the chlorpyrifos is adopted to construct a pesticide residue recognition, detection and sensing interface on the basis of the amplification effect of the magnetic molecularly imprinted polymer. Compared with the conventional pesticide residue detection technology, the surface plasma resonance sensor on the basis of the amplification effect of the magnetic molecularly imprinted polymer has high detection sensitivity and good selectivity to chlorpyrifos detection, and has an excellent application prospect.

A toxic material detection apparatus includes a sample collection portion including a sample inlet and a sample concentrator adapted to concentrate an environmental sample on a substrate. A sample distributing system transfers portions of the substrate to a color sensor and an ion mobility spectrometer for simultaneously analysis and toxin detection, particularly cholinesterase inhibitor detection. Optionally, a portion of the substrate may be directed to an archive for possible analysis at a later time. Reagents utilized include the enzyme acetylcholinesterase (AChE), and the reactants acetylthiocholine iodide (ATCI) and 5,5′-dithio-bis-(2-nitrobenzoic acid) (DTB). A data management unit provides for near-real-time analysis of the samples in under 5 minutes. Simultaneous “hits” by both analysis methods indicate the presence of a cholinesterase inhibitor.

The invention relates to an antisense oligonucleotide targeted to the coding region of the human acetylcholinesterase (AChE), which selectively suppresses the AChE-R isoform of the enzyme. The antisense oligonucleotide is intended for use in the treatment and/or prevention of neuromuscular disorders, preferably myasthenia gravis. In addition, it can penetrate the blood-brain barrier (BBB) and destroy AChE-R within central nervous system neurons, while also serving as a carrier to transport molecules across the BBB.

The invention relates to an acetylcholinesterase biosensor and an application thereof, and belongs to the technical field of electrochemical detection. The biosensor is produced through the following steps: 1, preparing a MnO2-nanoflakes composite nano-material and a Pd-Pt@MnO2-nanoflakes composite nano-material from KMnO4, CTAB, PdCl2, PEG400, H2PtCl6, sodium citrate and sodium borohydride used as initial raw materials through a water bath technology; and 2, immobilizing acetylcholinesterase by using chitosan (CS), and immobilizing acetylcholinesterase (AChE) on the surface of a Pd-Pt@MnO2 modified glassy carbon electrode through adopting physical adsorption to construct the electrochemical biosensor. The biosensor adopting an electrochemistry and enzyme sensing combination technology realizes high-sensitivity detection of methyl parathion and carbofuran pesticides, has the advantages of small amount of a required sample, short detection time, high sensitivity and low cost, and is suitable for analyzing and detecting pesticide residual.

The invention relates to the technical field of sensors, in particular to an acetylcholinesterase biological sensor. A method for manufacturing an electrochemical acetylcholinesterase biological sensor comprises the following steps of: manufacturing an enzyme membrane; modifying a glassy carbon electrode by using functionalized multi-wall carbon, namely functionalizing a multi-wall carbon nanotube, cleaning, testing and modifying; and fixing the enzyme membrane. Due to the technical scheme, the acetylcholinesterase biological sensor manufactured by the method has the advantages of simple structure, high sensitivity, repeated detection and the like.

The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an Aβ₄₂ lowering agent to a mammal under conditions in which levels of Aβ₄₂ are selectively reduced, levels of Aβ₃₈ are increased, and levels of Aβ₄₀ are unchanged. The invention provides methods and materials for developing and identifying Aβ₄₂ lowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease. The invention also provides compositions of Aβ₄₂ lowering agents and antioxidants, Aβ₄₂ lowering agents and non-selective secretase inhibitors, as well as Aβ₄₂ lowering agents and acetylcholinesterase inhibitors. The invention also provides kits containing Aβ₄₂ lowering agents, antioxidants, non-selective secretase inhibitors, and/or acetylcholinesterase inhibitors as well as instructions related to dose regimens for Aβ₄₂ lowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors.

The invention discloses a magnetic electrode based on Fe3O4-AuNPs magnetic composite nanoparticle immobilized acetylcholinesterase, belonging to the technical field of biosensors. Fe3O4-AuNPs magnetic composite nanoparticles are modified on a magnetic glassy carbon electrode through a magnetic force, and the magnetic glassy carbon electrode is used as a carrier to immobilize the acetylcholinesterase. A preparation method of the magnetic electrode comprises the following steps: firstly, preparing Fe3O4-AuNPs, then, preparing the magnetic glassy carbon electrode, dripping and coating 0.10 g/L CNTs (Carbon Nanotubes) turbid liquid, airing, then, putting the MGCE (Magnetic Glassy Carbon Electrode) in Fe3O4-AuNPs turbid liquid, adsorbing, washing, airing, and dripping and coating glutaraldehyde and AChE. The electrode disclosed by the invention has good conductivity and electrochemical properties.

The invention belongs to the technical field of medicine, and relates to a thiazolo(3,2-b)-1,2,4-triazine derivative and applications thereof. The thiazolo(3,2-b)-1,2,4-triazine derivative includes stereoisomers and pharmaceutically applicable salts of the compound, and has a general structural formula as shown follow. The thiazolo(3,2-b)-1,2,4-triazine derivative and the salts added by pharmaceutically applicable acids of the compound can be used by combining with the existing medicaments or separately as acetylcholinesterase inhibitors for enhancing the memory of patients suffering from dementia and alzheimer.

The invention relates to a kit for quickly detecting toxicity of pesticide residue, in particular to a kit for quickly detecting the toxicity of pesticide residue containing a mixture of acetylcholinesterase and butyryl cholinesterase. The kit consists of choline esterase, a substrate, a color-developing agent 5,5'-dithio-2-2'-dinitrobenzoic acid (DTNB) and phosphate buffer solution, wherein the choline esterase is the mixture containing the acetylcholinesterase and the butyryl cholinesterase, and the substrate contains butyrylthiocholine iodide.

A helicidum analog with high selective suppression to acetylcholinesterase and its application in preparing the medicines for preventing and treating senile dementia are disclosed.

Disclosed are methods for the preparation and use of labeled AChE and labeled AChE inhibitory conjugate compositions for detecting accumulation of toxic materials such as organophosphates, insecticides, and other nerve agents. Also disclosed are methods for the use of labeled AChE and labeled AChE inhibitory conjugate compositions in a variety of areas, including the detecting of toxic materials in biological samples, in the area of food and water analysis, in environmental monitoring, and in industrial settings.